Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000131.xml
Synfacts 2020; 16(05): 0495
DOI: 10.1055/s-0040-1707929
DOI: 10.1055/s-0040-1707929
Synthesis of Natural Products and Potential Drugs
Synthesis of BACE1 Inhibitor LY3202626
Garcia-Losada P.
*
Frederick M.
* et al. Centro de Investigación Lilly S.A., Alcobendas-Madrid, Spain and Lilly Research Laboratories, Windlesham, UK
Synthesis, Optimization, and Large-Scale Preparation of Low-Dose CNS-Penetrant BACE Inhibitor LY3202626 via a [3 + 2] Nitrone Cycloaddition.
Org. Process Res. Dev. 2020;
23: 306-314
Synthesis, Optimization, and Large-Scale Preparation of Low-Dose CNS-Penetrant BACE Inhibitor LY3202626 via a [3 + 2] Nitrone Cycloaddition.
Org. Process Res. Dev. 2020;
23: 306-314
Further Information
Publication History
Publication Date:
20 April 2020 (online)
Key words
LY3202626 - BACE1 inhibitor - [3+2] cycloaddition - nitrone - Buchwald C–N coupling - copper catalysis - aminothiazines
Significance
LY3202626 is a beta-secretase 1 (BACE1) inhibitor that was of interest for the treatment of Alzheimer’s disease. The key step in the large-scale synthesis depicted is the intramolecular [3+2] cycloaddition of nitrone E to give isoxazolidine rac-F.
#
Comment
The core bicyclic thiazine L was constructed by reaction of amine K with benzoyl isothiocyanate followed by cyclization of the resultant thiourea (not shown) using CDI. For the discovery synthesis of LY3202626, see: US 2014 0350245 A1.
#
#